---
title: "First transaction on the ChiNext! Ampron shareholders inquire about transfer, opening a new investment track"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/236722850.md"
description: "On the evening of April 18th, Ampron disclosed its first inquiry transfer plan on the Shenzhen Stock Exchange's ChiNext, organized and implemented by Huatai United Securities. This non-public transfer method has unique advantages, allowing participants to assess the company's value from a long-term perspective, which will not exert direct pressure on the secondary market stock price, helping to maintain stable market operations and the stable development of the enterprise"
datetime: "2025-04-21T04:46:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/236722850.md)
  - [en](https://longbridge.com/en/news/236722850.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/236722850.md)
generator: "portal-rs"
---

# First transaction on the ChiNext! Ampron shareholders inquire about transfer, opening a new investment track

On the evening of April 18, Ampron, a company listed on the Shenzhen Stock Exchange's ChiNext board, disclosed its inquiry transfer plan. It is noteworthy that this inquiry transfer is the first officially launched inquiry transfer by a ChiNext company. The announcement shows that the organizing broker for this inquiry transfer is Huatai United Securities. This non-public transfer method has many unique advantages. Unlike traditional centralized bidding transactions, investors participating in the inquiry transfer will examine the investment value of the listed company from a longer-term perspective, which means that the inquiry transfer will not exert direct pressure on the secondary market stock price, ensuring the stable operation of the market and providing strong support for the stable development of enterprises. (21st Century Business Herald)

### Related Stocks

- [301413.CN](https://longbridge.com/en/quote/301413.CN.md)

## Related News & Research

- [Serina Therapeutics Inc Reports Cohort 1 Observations From Ser-252 Registrational Study In Advanced Parkinson’S Disease And Advances To Cohort 2](https://longbridge.com/en/news/298452346.md)
- [Anatool Launches to Improve Recognition and Treatment of Anaphylaxis](https://longbridge.com/en/news/298492251.md)
- [Circadian Risk and RAD Bring Agentic AI to Enterprise Physical Risk Management with SARA Assess](https://longbridge.com/en/news/298460603.md)
- [SynAct Pharma bolsters resomelagon data as it readies Phase 3 and weighs strategic deals](https://longbridge.com/en/news/298195637.md)
- [EWG: Double-digit revenue growth and digital platform adoption drive robust margins and returns](https://longbridge.com/en/news/298417346.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**